2. Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy. In: Transactions of the Meeting of the American Surgical Association 2004;CXXII:242-56.
https://doi.org/10.1097/01.sla.0000141198.92114.f6
8. Bilchik AJ, Poston G, Curley SA, Strasberg S, Saltz L, Adam R, et al. Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note. J Clin Oncol 2005;23:9073–8.
10. Shanbhogue AK, Karnad AB, Prasad SR. Tumor response evaluation in oncology: current update. J Comput Assist Tomogr 2010;34:479–84.
11. Compton CC, Byrd DR, Garcia-Aguilar J, Kurtzman SH, Olawaiye A, Washington MK. Colon and rectum. In: Compton CC,Byrd DR,Garcia-Aguilar J,Kurtzman SH,Olawaiye A,Washington MK. editors. AJCC Cancer Staging Atlas: a companion to the Seventh Editions of the AJCC Cancer Staging Manual and Handbook. New York: Springer New York; 2012. p.185–201.
14. Khan H, Khan N, Ahmad A, Olszewski AJ, Somasundar P. Surgical management of metastatic colon cancer: A population-based analysis. J Geriatr Oncol 2015;6:446–53.
15. Chen HH, Lin JK, Chen JB, Chuang CH, Liu MC, Wang JY, et al. Neoadjuvant therapy of bevacizumab in combination with oxaliplatin and capecitabine (XELOX) for patients with metastatic colorectal cancer with unresectable liver metastases: a phase II, open-label, single-arm, noncomparative trial. Asia Pac J Clin Oncol 2018;14:61–8.
16. Devaud N, Kanji ZS, Dhani N, Grant RC, Shoushtari H, Serrano PE, et al. Liver resection after chemotherapy and tumour downsizing in patients with initially unresectable colorectal cancer liver metastases. HPB (Oxford) 2014;16:475–80.
17. Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010;11:38–47.
20. Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006;24:2065–72.